Short Interest in FibroGen Inc (NASDAQ:FGEN) Increases By 5.8%

FibroGen Inc (NASDAQ:FGEN) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 4,370,000 shares, an increase of 5.8% from the September 30th total of 4,130,000 shares. Approximately 5.8% of the shares of the company are short sold. Based on an average trading volume of 699,800 shares, the short-interest ratio is currently 6.2 days.

In related news, insider K Peony Yu sold 3,419 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $40.92, for a total value of $139,905.48. Following the sale, the insider now owns 175,240 shares in the company, valued at $7,170,820.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Christine Chung sold 5,625 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $34.74, for a total value of $195,412.50. Following the completion of the sale, the senior vice president now owns 145,253 shares in the company, valued at approximately $5,046,089.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,381 shares of company stock worth $3,839,495. Company insiders own 8.96% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in FibroGen by 8.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,726 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 378 shares during the period. Doheny Asset Management CA boosted its holdings in FibroGen by 1.6% in the 2nd quarter. Doheny Asset Management CA now owns 36,471 shares of the biopharmaceutical company’s stock worth $1,648,000 after buying an additional 586 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in FibroGen by 1.8% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 40,364 shares of the biopharmaceutical company’s stock worth $1,824,000 after buying an additional 720 shares during the period. Zacks Investment Management boosted its holdings in FibroGen by 2.8% in the 2nd quarter. Zacks Investment Management now owns 26,642 shares of the biopharmaceutical company’s stock worth $1,204,000 after buying an additional 738 shares during the period. Finally, Envestnet Asset Management Inc. lifted its stake in FibroGen by 4.1% in the 3rd quarter. Envestnet Asset Management Inc. now owns 22,334 shares of the biopharmaceutical company’s stock worth $826,000 after purchasing an additional 881 shares in the last quarter. 69.03% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts recently issued reports on the company. TheStreet upgraded FibroGen from a “d+” rating to a “c” rating in a research report on Tuesday, August 13th. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. Zacks Investment Research downgraded FibroGen from a “strong-buy” rating to a “hold” rating in a research report on Thursday. ValuEngine upgraded FibroGen from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Finally, Mizuho restated a “positive” rating and set a $72.00 price target (up previously from $65.00) on shares of FibroGen in a research report on Monday, November 11th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $58.33.

Shares of NASDAQ FGEN traded up $2.01 during trading hours on Friday, hitting $36.99. The company’s stock had a trading volume of 1,002,000 shares, compared to its average volume of 1,180,421. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.01. FibroGen has a 12 month low of $32.33 and a 12 month high of $61.23. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of -35.91 and a beta of 1.84. The business has a 50-day simple moving average of $38.31 and a 200-day simple moving average of $41.63.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.02. FibroGen had a net margin of 11.81% and a return on equity of 7.33%. The business had revenue of $33.17 million during the quarter, compared to the consensus estimate of $31.61 million. During the same quarter in the previous year, the firm posted ($0.50) EPS. The firm’s revenue was up 14.3% on a year-over-year basis. On average, equities research analysts forecast that FibroGen will post -0.16 EPS for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also: What is the Quick Ratio?

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit